Biochanin A Mitigates Pressure Overload-Induced Cardiac Hypertrophy Through Modulation of the NF-κB/Cbl-b/NLRP3 Signaling Axis

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2025 Feb 20

PMID 39976876

Authors

Lina Ba

Nan Wu

Xiang Feng

Ruixuan Wang

Zhichao Zhao

Rui Wang

Renling Liu

Pilong Shi

Hongli Sun

Hanping Qi

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to investigate the protective effects of biochanin A (BCA) on cardiac hypertrophy and to elucidate the underlying molecular mechanisms. The research question was whether BCA can reverse heart dysfunction and attenuate cardiomyocyte hypertrophy induced by pressure overload and AngII, respectively, and how it interacts with the NLRP3 pyroptosis pathway to achieve these effects.

Methods: We employed an animal model of pressure overload-induced cardiac hypertrophy and an in vitro model of AngII-induced cardiomyocyte hypertrophy to assess the effects of BCA. The expression of NLRP3 and its related signaling molecules was analyzed by western blotting, and the activity of the NLRP3 pathway was measured using pyroptosis assays. The role of Cbl-b, an E3 ubiquitin ligase, in BCA-mediated NLRP3 inhibition was also investigated.

Results: BCA was found to reverse heart dysfunction and attenuate cardiomyocyte hypertrophy induced by pressure overload and AngII. Mechanistically, BCA mitigated cardiac hypertrophy by targeting the NLRP3 pyroptosis pathway. The reduction in NLRP3 expression by BCA was predominantly mediated through the upregulation of Cbl-b, which enhanced the ubiquitination and subsequent degradation of NLRP3. Additionally, BCA facilitated the upregulation of Cbl-b expression by interacting with NF-κB, preventing NF-κB binding to the promoter region of Cbl-b and reversing its suppressive action on Cbl-b expression.

Conclusion: This study provides initial evidence that BCA can protect against cardiac hypertrophy. Its mechanism of action involves interacting with NF-κB to promote the expression of Cbl-b, which facilitates the ubiquitination and degradation of NLRP3, ultimately inhibiting pyroptosis. This finding suggests that BCA may be a potential therapeutic agent for the treatment of cardiac hypertrophy.

References

Kida K . Left ventricular hypertrophy was not built in a day. Hypertens Res. 2022; 46(2):341-342. DOI: 10.1038/s41440-022-01119-4. View

Volpe M, Gallo G . Hypertension, coronary artery disease and myocardial ischemic syndromes. Vascul Pharmacol. 2023; 153:107230. DOI: 10.1016/j.vph.2023.107230. View

Zhang X, Cai J, Li X, Chen X, Zhang Q . Left ventricular hypertrophy with cardiomyocyte atrophy and extensive interstitial fibrosis: a mitochondrial cardiomyopathy. Eur Heart J. 2022; 44(7):627. PMC: 9925271. DOI: 10.1093/eurheartj/ehac672. View

Liu Y, Lu H, Zhang C, Hu J, Xu D . Recent advances in understanding the roles of T cells in pressure overload-induced cardiac hypertrophy and remodeling. J Mol Cell Cardiol. 2019; 129:293-302. DOI: 10.1016/j.yjmcc.2019.01.005. View

Giamouzis G, Dimos A, Xanthopoulos A, Skoularigis J, Triposkiadis F . Left ventricular hypertrophy and sudden cardiac death. Heart Fail Rev. 2021; 27(2):711-724. DOI: 10.1007/s10741-021-10134-5. View

Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y . Pyroptosis: A new frontier in cancer. Biomed Pharmacother. 2019; 121:109595. DOI: 10.1016/j.biopha.2019.109595. View

Toldo S, Abbate A . The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol. 2023; 21(4):219-237. PMC: 11550901. DOI: 10.1038/s41569-023-00946-3. View

Yao J, Sterling K, Wang Z, Zhang Y, Song W . The role of inflammasomes in human diseases and their potential as therapeutic targets. Signal Transduct Target Ther. 2024; 9(1):10. PMC: 10766654. DOI: 10.1038/s41392-023-01687-y. View

Wang S, Yuan Y, Chen N, Wang H . The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. Int Immunopharmacol. 2018; 67:458-464. DOI: 10.1016/j.intimp.2018.12.019. View

10.

Chen X, Liu G, Yuan Y, Wu G, Wang S, Yuan L . NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-κB signaling. Cell Death Dis. 2019; 10(12):906. PMC: 6885517. DOI: 10.1038/s41419-019-2157-1. View

11.

Bai B, Yang Y, Wang Q, Li M, Tian C, Liu Y . NLRP3 inflammasome in endothelial dysfunction. Cell Death Dis. 2020; 11(9):776. PMC: 7501262. DOI: 10.1038/s41419-020-02985-x. View

12.

Zuo Y, Chen L, Gu H, He X, Ye Z, Wang Z . GSDMD-mediated pyroptosis: a critical mechanism of diabetic nephropathy. Expert Rev Mol Med. 2021; 23:e23. PMC: 8724266. DOI: 10.1017/erm.2021.27. View

13.

Yanpiset P, Maneechote C, Sriwichaiin S, Siri-Angkul N, Chattipakorn S, Chattipakorn N . Gasdermin D-mediated pyroptosis in myocardial ischemia and reperfusion injury: Cumulative evidence for future cardioprotective strategies. Acta Pharm Sin B. 2023; 13(1):29-53. PMC: 9939317. DOI: 10.1016/j.apsb.2022.08.007. View

14.

Wu J, Dong E, Zhang Y, Xiao H . The Role of the Inflammasome in Heart Failure. Front Physiol. 2021; 12:709703. PMC: 8581560. DOI: 10.3389/fphys.2021.709703. View

15.

Zhu Y, Wang R, Chen W, Cao Y, Li L, Chen X . miR-133a-3p attenuates cardiomyocyte hypertrophy through inhibiting pyroptosis activation by targeting IKKε. Acta Histochem. 2020; 123(1):151653. DOI: 10.1016/j.acthis.2020.151653. View

16.

Nestel P, Pomeroy S, Kay S, Komesaroff P, Behrsing J, Cameron J . Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab. 1999; 84(3):895-8. DOI: 10.1210/jcem.84.3.5561. View

17.

Yan J, Qiu P, Zhang X, Zhang Y, Mi L, Peng C . Biochanin A from Chinese Medicine: An Isoflavone with Diverse Pharmacological Properties. Am J Chin Med. 2021; 49(7):1623-1643. DOI: 10.1142/S0192415X21500750. View

18.

Sarfraz A, Javeed M, Shah M, Hussain G, Shafiq N, Sarfraz I . Biochanin A: A novel bioactive multifunctional compound from nature. Sci Total Environ. 2020; 722:137907. DOI: 10.1016/j.scitotenv.2020.137907. View

19.

Yu X, Chen J, Deng W, Xu X, Liu Q, Shi M . Biochanin A Mitigates Atherosclerosis by Inhibiting Lipid Accumulation and Inflammatory Response. Oxid Med Cell Longev. 2021; 2020:8965047. PMC: 8074550. DOI: 10.1155/2020/8965047. View

20.

Bai Y, Li Z, Liu W, Gao D, Liu M, Zhang P . Biochanin A attenuates myocardial ischemia/reperfusion injury through the TLR4/NF-κB/NLRP3 signaling pathway. Acta Cir Bras. 2019; 34(11):e201901104. PMC: 6917477. DOI: 10.1590/s0102-865020190110000004. View